The treatment of one of the most common urological diseases, a chronic aseptic prostatitis, is an exigeant problem. Used methods of pharmacotherapy are insufficiently effective and after treatment, as a rule, there co...The treatment of one of the most common urological diseases, a chronic aseptic prostatitis, is an exigeant problem. Used methods of pharmacotherapy are insufficiently effective and after treatment, as a rule, there comes a recrudescence. The efficiency of new prostatotropic agent Prostamax is studied in the present work, this drug is related to bioregulator peptides at experimental chronic aseptic inflammation of prostate gland. It is established that Prostamax reduces intensity of signs of a chronic inflammation (swelling, hyperemia of vessels, lymphoid infiltration), prevents development of sclerotic and atrophic processes. It is shown that the agent intensifies sexual activity of animals. Efficiency of the preparation Prostamax surpasses that among widespread prostatotropic agents derived from the extract of Serenoa repens and prostate of animals.展开更多
Experimental evaluation of efficiency of a new prostatotropic medication tertapeptide lysil-glutamyl-aspartyl-proline (Lys-Glu-Asp-Pro)?in treatment of benign prostatic hyperplasia was performed in Wistar rats. The ef...Experimental evaluation of efficiency of a new prostatotropic medication tertapeptide lysil-glutamyl-aspartyl-proline (Lys-Glu-Asp-Pro)?in treatment of benign prostatic hyperplasia was performed in Wistar rats. The efficiency of the medication was compared with that one of injections of the?Serenoa repensextract. The investigation showed the statistically significant decrease in the square of the epithelium of acini. The same effect of similar severity was obtained when the?Serenoa repens?extract was applied. Tertapeptide Lys-Glu-Asp-Pro, in difference from?Serenoa repens?extract, also resulted in weight loss and volume decrease of the prostate gland.展开更多
文摘The treatment of one of the most common urological diseases, a chronic aseptic prostatitis, is an exigeant problem. Used methods of pharmacotherapy are insufficiently effective and after treatment, as a rule, there comes a recrudescence. The efficiency of new prostatotropic agent Prostamax is studied in the present work, this drug is related to bioregulator peptides at experimental chronic aseptic inflammation of prostate gland. It is established that Prostamax reduces intensity of signs of a chronic inflammation (swelling, hyperemia of vessels, lymphoid infiltration), prevents development of sclerotic and atrophic processes. It is shown that the agent intensifies sexual activity of animals. Efficiency of the preparation Prostamax surpasses that among widespread prostatotropic agents derived from the extract of Serenoa repens and prostate of animals.
文摘Experimental evaluation of efficiency of a new prostatotropic medication tertapeptide lysil-glutamyl-aspartyl-proline (Lys-Glu-Asp-Pro)?in treatment of benign prostatic hyperplasia was performed in Wistar rats. The efficiency of the medication was compared with that one of injections of the?Serenoa repensextract. The investigation showed the statistically significant decrease in the square of the epithelium of acini. The same effect of similar severity was obtained when the?Serenoa repens?extract was applied. Tertapeptide Lys-Glu-Asp-Pro, in difference from?Serenoa repens?extract, also resulted in weight loss and volume decrease of the prostate gland.
